Myrexis

Myrexis Forward P/E

Forward P/E Ratio of Myrexis (MYRX) as of Oct 18, 2026.

Forward P/E

-0.00

Last updated:

Forward P/E Ratio of Myrexis is 2013 -0.00 . Forward P/E Ratio of Myrexis was 2012 - . It decreases by % lower compared to the previous year.

The Myrexis Forward P/E history

The Myrexis Forward P/E history
YEARForward P/EYoY
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myrexis Stock analysis

What does Myrexis do? Myrexis Inc., based in New York City, operates in the Health Care sector with a focus on Biotechnology. The company evaluates strategic alternatives, including financial investments in life sciences assets, and previously developed drug candidates in oncology and autoimmune diseases. It suspended clinical development in 2012 and aims to build a commercial-stage biopharmaceutical company. Myrexis employs one full-time employee and conducts research and development activities primarily within the United States. Myrexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myrexis stock

On Eulerpool you can find the complete historical development of Forward P/E Ratio Myrexis since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Myrexis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Myrexis

All Key Metrics — Myrexis